Shionogi's Xocova Extends Global Reach Through First MPP Sublicenses

 
• By Lisa Takagi

The first sublicensing deals through MPP for Shionogi's oral COVID antiviral Xocova with seven firms in China, India, Ukraine and Vietnam suggest the global debut of generic versions will come earlier than usual after the original, which continues in multiple global Phase III programs in various settings. While sales hopes are high, the drug may also be hit by a price cut in its first and biggest market so far – Japan.  

Xocova's sublicensing deal suggests its global debut may come earlier than the original product.
Xocova's sublicensing deal to provide drug in 117 low- and-middle-income countries. • Source: Shutterstock

More from Business

More from Scrip